Calidi Biotherapeutics Stock Market Value
| CLDI Stock | 1.02 0.03 2.86% |
| Symbol | Calidi |
Is there potential for Biotechnology market expansion? Will Calidi introduce new products? Factors like these will boost the valuation of Calidi Biotherapeutics. Projected growth potential of Calidi fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Understanding Calidi Biotherapeutics requires distinguishing between market price and book value, where the latter reflects Calidi's accounting equity. The concept of intrinsic value—what Calidi Biotherapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Calidi Biotherapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Calidi Biotherapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Calidi Biotherapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Calidi Biotherapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Calidi Biotherapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Calidi Biotherapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Calidi Biotherapeutics.
| 11/02/2025 |
| 01/31/2026 |
If you would invest 0.00 in Calidi Biotherapeutics on November 2, 2025 and sell it all today you would earn a total of 0.00 from holding Calidi Biotherapeutics or generate 0.0% return on investment in Calidi Biotherapeutics over 90 days. Calidi Biotherapeutics is related to or competes with Clearmind Medicine, Can Fite, Kazia Therapeutics, Silo Pharma, CNS Pharmaceuticals, 60 Degrees, and Xenetic Biosciences. Calidi Biotherapeutics is entity of United States More
Calidi Biotherapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Calidi Biotherapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Calidi Biotherapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 24.52 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 4.9 |
Calidi Biotherapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Calidi Biotherapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Calidi Biotherapeutics' standard deviation. In reality, there are many statistical measures that can use Calidi Biotherapeutics historical prices to predict the future Calidi Biotherapeutics' volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.54) | |||
| Total Risk Alpha | (0.78) | |||
| Treynor Ratio | (1.07) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Calidi Biotherapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Calidi Biotherapeutics January 31, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (1.06) | |||
| Mean Deviation | 2.74 | |||
| Coefficient Of Variation | (744.66) | |||
| Standard Deviation | 3.78 | |||
| Variance | 14.27 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.54) | |||
| Total Risk Alpha | (0.78) | |||
| Treynor Ratio | (1.07) | |||
| Maximum Drawdown | 24.52 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 4.9 | |||
| Skewness | (0.29) | |||
| Kurtosis | 2.3 |
Calidi Biotherapeutics Backtested Returns
Calidi Biotherapeutics secures Sharpe Ratio (or Efficiency) of -0.15, which signifies that the company had a -0.15 % return per unit of risk over the last 3 months. Calidi Biotherapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Calidi Biotherapeutics' Standard Deviation of 3.78, risk adjusted performance of (0.09), and Mean Deviation of 2.74 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.48, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Calidi Biotherapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Calidi Biotherapeutics is expected to be smaller as well. At this point, Calidi Biotherapeutics has a negative expected return of -0.59%. Please make sure to confirm Calidi Biotherapeutics' treynor ratio, accumulation distribution, period momentum indicator, as well as the relationship between the potential upside and day median price , to decide if Calidi Biotherapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.21 |
Weak predictability
Calidi Biotherapeutics has weak predictability. Overlapping area represents the amount of predictability between Calidi Biotherapeutics time series from 2nd of November 2025 to 17th of December 2025 and 17th of December 2025 to 31st of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Calidi Biotherapeutics price movement. The serial correlation of 0.21 indicates that over 21.0% of current Calidi Biotherapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.21 | |
| Spearman Rank Test | 0.12 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Currently Active Assets on Macroaxis
When determining whether Calidi Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Calidi Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Calidi Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Calidi Biotherapeutics Stock:Check out Calidi Biotherapeutics Correlation, Calidi Biotherapeutics Volatility and Calidi Biotherapeutics Performance module to complement your research on Calidi Biotherapeutics. For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Calidi Biotherapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.